Detection of ROS1 rearrangement in non-small cell lung cancer: current and future perspectives.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

25 citing papers in PubMed, 53 citations in OpenAlex.

1. Single-nucleus multi-omics delineates distinct epigenetic programs associated with tumor progression in lung adenocarcinoma.Clinical epigenetics · 2026
   Article
2. Frontiers in oncology · 2026
   Review
3. Effectiveness of First-Line Treatment with Anaplastic Lymphoma Kinase and ROS1 Protoncogene Inhibitors in Non-Small Cell Lung Cancer Patients-Real-World Evidence of Two Polish Cancer Centers.Cancers · 2025
   Article
4. Exceptional long term response to crizotinib in ROS 1-postive advanced non small cell lung cancer.Respirology case reports · 2024
   Article
5. Clinical and economic impact of 'ROS1-testing' strategy compared to a 'no-ROS1-testing' strategy in advanced NSCLC in Spain.BMC cancer · 2022
   Article
6. Deepening the Knowledge ofInternational journal of molecular sciences · 2021
   Review
7. Reflex ROS1 IHC Screening with FISH Confirmation for Advanced Non-Small Cell Lung Cancer-A Cost-Efficient Strategy in a Public Healthcare System.Current oncology (Toronto, Ont.) · 2021
   Article
8. ROS1 Targeted Therapies: Current Status.Current oncology reports · 2021
   Review
9. Optimized workflow for digitalized FISH analysis in pathology.Diagnostic pathology · 2021
   Article
10. ROS1-dependent cancers - biology, diagnostics and therapeutics.Nature reviews. Clinical oncology · 2021
    Review
11. NRG1 fusion-driven tumors: biology, detection, and the therapeutic role of afatinib and other ErbB-targeting agents.Annals of oncology : official journal of the European Society for Medical Oncology · 2020
    Review
12. Oncology letters · 2020
    Article
13. [Chinese Expert Consensus on Next Generation Sequencing Diagnosis 
for Non-small Cell Lung Cancer (2020 Edition)].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2020
    Article
14. Clinical characteristics of patients withTranslational cancer research · 2020
    Article
15. Treatment of coronavirus disease 2019 in Shandong, China: a cost and affordability analysis.Infectious diseases of poverty · 2020
    Article
16. Immunization against ROS1 by DNA Electroporation Impairs K-Ras-Driven Lung Adenocarcinomas ​.Vaccines · 2020
    Article
17. The Current Understanding Of Asbestos-Induced Epigenetic Changes Associated With Lung Cancer.Lung Cancer (Auckland, N.Z.) · 2020
    Review
18. Comparison of next-generation sequencing and immunohistochemistry analysis for targeted therapy-related genomic status in lung cancer patients.Journal of thoracic disease · 2019
    Article
19. Clinic-pathologic features and gene fusion pattern of ALK and ROS1 in non-small cell lung cancer show association with household coal combustion.Translational cancer research · 2019
    Article
20. Crizotinib inhibition ofCurrent oncology (Toronto, Ont.) · 2019
    Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

10 authors at 7 institutions in 3 countries.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as